1

ERYTHEMA MULTIFORME

12/29/2013
INTRODUCTION
2

 Erythema – Redness ; Multiforme – Polymorphic
 First Classified by Bastuji – Garin et al to separate

from SJS / TEN in 1922
 described by Hebra in 1866 as Erythema

exudativum Multiforme

12/29/2013
DEFINITION
3

 Acute, Recurrent, self-limiting Cutaneous and/or

Mucocutaneous eruptions characterised by target –
shaped plaques commonly over extremities and
face.
 Assoc with HSV / Mycoplasma pneumonia infections

12/29/2013
EPIDEMIOLOGY
4

 Male : Female = 3:2
 Occurs in the young / adoloscents
 Recurrent in 30 %
 Familial clustering s/o Infective Etiology
 Assoc with HLA – DQB1 * 0301 Allele
12/29/2013
AETIOLOGY
5

12/29/2013
CLASSIFICATION
6

 EM Minor : Cutaneous without Mucous inv
 EM Major (EMM) : Cutaneous + Mucous inv
 Mucosal EM : Fuch’s Ectodermosis Pluriorificialis
 HAEM
 MPAEM
12/29/2013
CLINICAL FEATURES
7

Prodromal Features
Prev Attack (30%)
Preceding Infection
Fever (T>103.1 deg C)
Cutaneous Lesions
Mucous Lesions

12/29/2013
CUTANEOUS LESIONS
8

 Symmetrical, Acral, Centripetal Rash
 Extensor aspect : Extremities > Face > Neck > Trunk
 Predilection to Sun-Exposed Areas / Koebnerization
 Well-defined, circular, blanching papule / plaque that

persists for 01 week – Self-limiting in 04 weeks –
Persistent / Continuous EM
12/29/2013
CUTANEOUS LESIONS
9

 Typical Target Lesion :-

1. Dusky Central Disk / Bulla
(later Violaceous / Purpuric)
2. Infiltrated Pale Ring
3. Erythematous edematous halo
Larger lesions show Central
Bulla and Marginal ring of vesicles - Herpes Iris of Bateman
12/29/2013
TARGET LESIONS
10

12/29/2013
CUTANEOUS LESIONS
11

 Raised Atypical Target lesions / Targetoid lesions

 SJS-TEN lesions – mostly Macular

12/29/2013
MUCOSAL LESIONS
12

 70% Cases
 Lips – Cutaneous

Target Lesions
Serous Crusting

12/29/2013
MUCOSAL LESIONS
13

 LIPS – Mucosal (Erosions / Vesicles / Bullae)
 GINGIVAL / Ventral Tongue
 Hard Palate – Spared
 Pharynx / Larynx / Trachea / Bronchi
 Conjunctivitis B/L with Vesicles / Erosions
 Nasal / Urethral / Anal Mucosae
 2/3 Mucosal Sites sans Cutaneous inv

– FUCH’s SYNDROME
12/29/2013
14

12/29/2013
15

 aa

12/29/2013
DDx
16

ss

12/29/2013
17

12/29/2013
TREATMENT
18

 Treating underlying Etiology
 Reducing morbidity – Oral CS
 Anti-Virals ?
 Macrolides / Quinolones for MPAEM
 Oral EM – Topical CS / Anesthetics / Antacids
12/29/2013
RECURRENT EM
19

 Anti-Virals
 Topical Acyclovir ?
 Azathioprine
 Thalidomide

12/29/2013
20

THANK YOU

12/29/2013

Erythema multiforme by aseem